Recalls & Alerts Published by NAFDAC

The National Agency for Food and Drug Administration and Control has been notified that the British Medicines and Healthcare Products Regulatory Agency (MHRA) have announced the global recall of various High Concentration Oxygen Masks manufactured by ConvaTec and Unomedical. High Concentration Oxygen Masks are intended to deliver high concentration oxygen to patient airways.

Reason for recall

  •  Product reports confirmed that the devices are not meeting the desired expectation.
  •  In some cases, the tubing was found to be disconnecting from the oxygen mask, prior to use or during use causing disruption in oxygen supply.

The details of the affected batches are as follows;

Manufacturer’s Address: ConvaTec Limited, First Avenue, Deeside Industrial Park,

                                            Deeside, CH5 2NU, U.K.

Product Code / REF No. SAP Code Description LOT No's.
104MM 1302097 Rebreathing mask, Reservoir bag, with Tubing 105631

106MM

1702436

Oxygen Mask, Adult High Concentration Non-Rebreather 2.1m (7') Oxygen Tubing

100733,104106,104798,100721,109824

108-E 1300168 Non-Rebreather Oxygen Mask, Adult High Concentration with 2.1m (7’) Oxygen Tubing

102766,102785,102726,102352,105451,

109186

108MM 1705302 Non-Rebreather Oxygen Mask, Adult High Concentration with 2.1m (7’) Oxygen Tubing

100281,100709,100729,101923,103180,

103265,103691,103714,104104,105987,

110558

3226-E 1308753 Non-Rebreather Oxygen Mask, Pediatric High Concentration with 2.1m (7’) Oxygen Tubing 102727
3226MM 1307553 Non-Rebreather Oxygen Mask, Pediatric High Concentration with 2.1m (7’) Oxygen Tubing 100720,101141
3230MM 1302405 Non-Rebreather Oxygen Mask, Pediatric High Concentration with 2.1m (7’) Oxygen Tubing 104906,105181
9108MM 126152 Non-Rebreather Oxygen Mask, Adult High Concentration with 2.1m (7’) Oxygen Tubing

100232,100694,100918,101639,101897,

103067,104846,104848,105453

       

Healthcare Provider’s Action

  • Healthcare providers in possession of these affected products should stop using them.
  • Healthcare providers and patients are encouraged to report adverse events associated with the use of these products to the nearest NAFDAC office, NAFDAC PRASCOR (20543 TOLL FREE from all networks) or via This email address is being protected from spambots. You need JavaScript enabled to view it.

NAFDAC……..Safeguarding the Health of the Nation!!!

The National Agency for Food and Drug Administration and Control has been notified by the U.S. Food and Drug Administration (U.S. FDA) of its approval of label changes regarding the use of general anesthetic and sedation medicines in children younger than 3 years.

These general anesthetic and sedation drugs are necessary for surgery or other painful and stressful procedures in patients including infants, children and pregnant women. They are administered intravenously or by inhalation to render a patient reversibly unconscious and unresponsive in order to allow surgeons operate on the patient.

The label changes include the following warnings;

  • Exposure to these medicines for lengthy periods of time or over multiple surgeries or procedures may negatively affect brain development in children younger than 3 years.
  • Exposure to the use of these medicines on pregnant and pediatric patients for more than 3 hours can cause widespread loss of nerve cells in the developing brain. Studies in young animals suggested these changes resulted in long-term negative effects on the animals’ behavior or learning.

Healthcare Provider Action

  • Continue to ensure patients counseling and discussion on the benefits and risks of surgeries or procedures that require general anesthesia and sedation drugs.
  • Parents, caregivers and pregnant women should be encouraged to ask questions on their concerns about these medicines.
  • Healthcare providers as well as patients are encouraged to report adverse events or side effects related to the of these medicines to NAFDAC PRASCOR (20543-Toll free from all networks) or via This email address is being protected from spambots. You need JavaScript enabled to view it.

NAFDAC.........Safeguarding the Health of the Nation!!!

The attention of the Agency has been drawn to the FDA’s alert to physicians who care for pregnant women meeting CDC Zika virus clinical criteria and/or CDC Zika virus epidemiological criteria, that the U.S. commercial testing facility, Laboratory Corporation of America (LabCorp). It has been reported that some false positive results from the ZIKV Detect test. The FDA has not yet determined if the reported false positives are related to the ZIKV Detect test or the commercial testing facility. While the FDA has not yet determined if the reported false positives are related to the ZIKV Detect test or the commercial testing facility, it is important to remember that IgM tests remain useful in ruling out Zika exposure but require confirmatory testing.

The ZIKV Detect IgM Capture ELISA is used for the preliminary (presumptive) detection of Zika virus IgM antibodies in human sera collected from patients with a history of clinical signs and symptoms associated with Zika virus infection (Centers for Disease Control and Prevention [CDC] clinical criteria for Zika virus) and/or a history of residence in or travel to a geographic region with active Zika transmission at the time of travel (CDC Zika virus epidemiological criteria).

 

Healthcare providers’ action

Inform their patients that presumptive positive results need to be confirmed, so that pregnant women are not making health care decisions based on incomplete information.

Don’t rely on presumptive positive Zika virus IgM test results as the sole basis of significant patient management decisions.

Notify the laboratory of the patient’s pregnancy to facilitate prioritization of confirmatory testing by CDC or disqualified laboratories.

Report adverse events or side effects related to the use of the product to NAFDAC PRASCOR (20543, toll free from all network) or via individual case safety report forms or via email: This email address is being protected from spambots. You need JavaScript enabled to view it. and also encourage patients to do same.

Page 2 of 8

ONLINE PORTALS

napams

Contact Us from Mon - Friday: 08:00-16:00 GMT+1

Write Us:

NAFDAC Corporate Headquarters,

Plot 2032, Olusegun, Obasanjo Way,

Zone 7, Wuse, Abuja, Nigeria

 

Lagos Operation Office:

Plot 1, Industrial Estate, Lagos- Oshodi Apapa Express Way, Isolo, Lagos, Nigeria

 

 

 

 

 

 

For Enquiries:

Call: +234(0)-1-4609750

Email:nafdac@nafdac.gov.ng

 

 

 

 

 

 

 

 

 

 

For Complaints:

Call: +234(0)907630506

Email:reforms@nafdac.gov.ng

Or Send Us a Complaint

 

 

 

 

 

 

 

 

 

Contact Other NAFDAC Offices Nationwide